Experienced life sciences investment manager Deepbridge Capital has today (19 June 2017) announced the launch of Deepbridge Syndicate, an online investment platform created to facilitate investment by elective professional investors in to healthcare innovation.

Deepbridge has invested in over 35 life sciences companies to date and aims to provide Deepbridge Syndicate investors with the reassurance of their ongoing engagement and investment in rigorously selected investment opportunities.

Investing in Life Sciences has never been more vital, with the ageing population, prevalence of mental health concerns and the ever-increasing pressure on national and international healthcare services. There is a growing need and market for medical innovation, which are being developed at a faster rate than ever before, providing considerable opportunities for investors to access growth-focused and revenue generating investment opportunities.

The UK life sciences sector is unique and can represent a challenging environment for even experienced investors to identify appropriate opportunities and value.  Deepbridge’s sector experience enables investors to better identify life sciences growth opportunities, which have been appropriately valued and will be actively managed by the Deepbridge life sciences team, headed by Dr Savvas Neophytou.

Investors via Deepbridge Syndicate must qualify to be treated as an Elective Professional Client in line with the definition of the Market in Financial Instruments Directive.

Deepbridge Syndicate: www.deepbridgesyndicate.com

Ian Warwick, Managing Partner at Deepbridge Capital, commented;

“The UK is at the global forefront of life sciences innovation, on a par with premier life science destinations such as Boston, San Francisco, San Diego and Singapore. The UK sector consists of over 5,700 companies employing over 231,000 with an annual turnover of around £61.8bn[1]. The rising wealth in emerging economies such as China, India and Brazil continues to open up new opportunities for medical and biopharmaceutical companies.

Deepbridge Syndicate aims to open up this market potential to the individual investor. Traditionally, investing in Life Sciences hasn’t been easy to access for many investors as the technologies, valuations and exits opportunities are often difficult calculate, but with the due diligence and proactive management from Deepbridge Capital and online access to key documents and updates via the Syndicate, investors are constantly in touch with the progress of their investment.  A majority of the portfolio companies also benefit from the UK Government’s Enterprise Investment Scheme (EIS), which provides considerable tax relief to those investing in these higher risk companies.”

Deepbridge Syndicate is launching with 3 Life Sciences companies on the platform, all of which have also received funding via the Deepbridge Technology Growth EIS or Deepbridge Life Sciences (S)EIS  portfolios: